Author

M. Smith

Institution: Research Advocacy Network

Observed institution: Research Advocacy Network

OpenAlex ID: A5126259698

Abstract GS1-04: Tumor infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in stage II/III HER2+ breast cancer treated with taxane, trastuzumab, and pertuzumab (THP): secondary results from the ECOG-ACRIN EA1181/CompassHER2 pCR trial

2026 · S. S. Badve, F. Zhao, et al. · Clinical Cancer Research

Works count: 1

Citation count:

H-index:

I10-index: